HomeCompareREVBU vs BTI

REVBU vs BTI: Dividend Comparison 2026

REVBU yields 690.37% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REVBU wins by $810427.03M in total portfolio value
10 years
REVBU
REVBU
● Live price
690.37%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$810427.07M
Annual income
$630,711,075,666.81
Full REVBU calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — REVBU vs BTI

📍 REVBU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREVBUBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REVBU + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REVBU pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REVBU
Annual income on $10K today (after 15% tax)
$58,681.39/yr
After 10yr DRIP, annual income (after tax)
$536,104,414,316.79/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, REVBU beats the other by $536,104,411,948.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REVBU + BTI for your $10,000?

REVBU: 50%BTI: 50%
100% BTI50/50100% REVBU
Portfolio after 10yr
$405213.55M
Annual income
$315,355,539,226.73/yr
Blended yield
77.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

REVBU
Analyst Ratings
1
Buy
Consensus: Buy
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REVBU buys
0
BTI buys
0
No recent congressional trades found for REVBU or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREVBUBTI
Forward yield690.37%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$810427.07M$37.7K
Annual income after 10y$630,711,075,666.81$2,786.64
Total dividends collected$795837.92M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: REVBU vs BTI ($10,000, DRIP)

YearREVBU PortfolioREVBU Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$79,737$69,036.93$11,299$598.92+$68.4KREVBU
2$599,785$514,466.69$12,794$703.91+$587.0KREVBU
3$4,258,447$3,616,676.77$14,518$829.07+$4.24MREVBU
4$28,554,890$23,998,351.37$16,513$978.64+$28.54MREVBU
5$180,946,473$150,392,741.11$18,827$1,157.84+$180.93MREVBU
6$1,084,274,338$890,661,611.68$21,518$1,373.12+$1084.25MREVBU
7$6,148,076,706$4,987,903,165.00$24,657$1,632.46+$6148.05MREVBU
8$33,010,704,292$26,432,262,216.06$28,329$1,945.74+$33010.68MREVBU
9$167,958,874,690$132,637,421,097.63$32,637$2,325.33+$167958.84MREVBU
10$810,427,071,585$630,711,075,666.81$37,708$2,786.64+$810427.03MREVBU

REVBU vs BTI: Complete Analysis 2026

REVBUStock

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Full REVBU Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this REVBU vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REVBU vs SCHDREVBU vs JEPIREVBU vs OREVBU vs KOREVBU vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.